Moderna's mRNA Cancer Prevention Vaccine for Lynch Syndrome Authorized for UK Phase 1/2 Study
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna and the University of Oxford received UK authorization to begin a Phase 1/2 study for mRNA-4194, an investigational mRNA cancer vaccine targeting Lynch Syndrome. This marks Moderna's first cancer prevention program, expanding its mRNA platform beyond infectious diseases into a new, high-need therapeutic area. Lynch Syndrome affects 1 in 300 people and carries up to an 80% lifetime cancer risk. This early-stage clinical progression is a positive step for Moderna's long-term pipeline diversification. The first patient is expected to be dosed this summer.
At the time of this announcement, MRNA was trading at $47.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.9B. The 52-week trading range was $22.28 to $59.55. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.